Biodesix Announces One-for-Twenty Reverse Stock Split

Core Viewpoint - Biodesix, Inc. announced a one-for-twenty reverse stock split effective September 15, 2025, aimed at reducing the number of outstanding shares and potentially improving the stock's market perception [1][2]. Group 1: Reverse Stock Split Details - The reverse stock split was approved by stockholders on May 20, 2025, with the final ratio determined by the board of directors [2]. - The number of shares will decrease from approximately 156 million to about 8 million, with adjustments for fractional shares [2]. - The reverse stock split will not change stockholders' percentage ownership interests, except for fractional shares, which will be compensated in cash [3]. Group 2: Impact on Equity Incentive Plans - The number of shares available under the Company's equity incentive plans and the exercise prices of outstanding options and warrants will be proportionately adjusted [4]. Group 3: Administrative Process - Computershare Trust Company, N.A. will act as the transfer agent, managing the transition to post-split shares without requiring action from registered stockholders [5]. - Stockholders with certificated shares will receive instructions from Computershare on how to surrender their pre-split shares [5]. Group 4: Company Overview - Biodesix is a leader in personalized diagnostics, focusing on improving clinical care and outcomes for patients, particularly in lung disease [7].